ImmuneOnco secures FDA IND clearance for Phase Ib/II study of dual-targeting antibody IMM0306 in systemic lupus erythematosus

Bulletin Express

08/21

Hong Kong-listed ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B, 01541) reported that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for IMM0306, authorising a Phase Ib/II clinical trial in systemic lupus erythematosus (SLE).

IMM0306 is a bispecific molecule that simultaneously targets CD47 and CD20. By blocking the CD47-SIRPα “don’t eat me” signal and enhancing Fc-mediated activation of macrophages and natural killer cells, the agent is designed to eliminate malignant B-cells while limiting toxicity. According to the company, IMM0306 is the first CD47/CD20 dual-targeting bispecific antibody to enter clinical development worldwide, and ImmuneOnco retains full global intellectual property and commercial rights.

The announcement, dated 21 August 2026, is voluntary under Hong Kong listing rules. The company reiterates that successful development or commercialisation of IMM0306 is not assured and advises shareholders and potential investors to exercise caution when dealing in its shares.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1119750546"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1119750546\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1119750546?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-21 20:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119750546","market":"hk","top_or_hot":-1,"title":"ImmuneOnco secures FDA IND clearance for Phase Ib/II study of dual-targeting antibody IMM0306 in systemic lupus erythematosus","media":"Bulletin Express","content":"<p>Hong Kong-listed ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B, 01541) reported that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for IMM0306, authorising a Phase Ib/II clinical trial in systemic lupus erythematosus (SLE).</p>\n<p>IMM0306 is a bispecific molecule that simultaneously targets CD47 and CD20. By blocking the CD47-SIRPα “don’t eat me” signal and enhancing Fc-mediated activation of macrophages and natural killer cells, the agent is designed to eliminate malignant B-cells while limiting toxicity. According to the company, IMM0306 is the first CD47/CD20 dual-targeting bispecific antibody to enter clinical development worldwide, and ImmuneOnco retains full global intellectual property and commercial rights.</p>\n<p>The announcement, dated 21 August 2026, is voluntary under Hong Kong listing rules. The company reiterates that successful development or commercialisation of IMM0306 is not assured and advises shareholders and potential investors to exercise caution when dealing in its shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmuneOnco secures FDA IND clearance for Phase Ib/II study of dual-targeting antibody IMM0306 in systemic lupus erythematosus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuneOnco secures FDA IND clearance for Phase Ib/II study of dual-targeting antibody IMM0306 in systemic lupus erythematosus\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-08-21 20:45</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Hong Kong-listed ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B, 01541) reported that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for IMM0306, authorising a Phase Ib/II clinical trial in systemic lupus erythematosus (SLE).</p>\n<p>IMM0306 is a bispecific molecule that simultaneously targets CD47 and CD20. By blocking the CD47-SIRPα “don’t eat me” signal and enhancing Fc-mediated activation of macrophages and natural killer cells, the agent is designed to eliminate malignant B-cells while limiting toxicity. According to the company, IMM0306 is the first CD47/CD20 dual-targeting bispecific antibody to enter clinical development worldwide, and ImmuneOnco retains full global intellectual property and commercial rights.</p>\n<p>The announcement, dated 21 August 2026, is voluntary under Hong Kong listing rules. The company reiterates that successful development or commercialisation of IMM0306 is not assured and advises shareholders and potential investors to exercise caution when dealing in its shares.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"","article_id":"1119750546","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119750546","pubTimestamp":1787316325,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong-listed ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B, 01541) reported that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B"},"translate_title":"ImmuneOnco获得FDA IND批准，用于双靶向抗体IMM0306治疗系统性红斑狼疮的Ib/II期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1},"content_text":"Hong Kong-listed ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B, 01541) reported that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for IMM0306, authorising a Phase Ib/II clinical trial in systemic lupus erythematosus (SLE).\nIMM0306 is a bispecific molecule that simultaneously targets CD47 and CD20. By blocking the CD47-SIRPα 「don’t eat me」 signal and enhancing Fc-mediated activation of macrophages and natural killer cells, the agent is designed to eliminate malignant B-cells while limiting toxicity. According to the company, IMM0306 is the first CD47/CD20 dual-targeting bispecific antibody to enter clinical development worldwide, and ImmuneOnco retains full global intellectual property and commercial rights.\nThe announcement, dated 21 August 2026, is voluntary under Hong Kong listing rules. The company reiterates that successful development or commercialisation of IMM0306 is not assured and advises shareholders and potential investors to exercise caution when dealing in its shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}